GlassScriptPhysician profile
Naveed Sheikh
NPI 1477794873
$3,635.38
in general payments reported to CMS, 2019-2025
26 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2021: $44.02 · 2022: $285 · 2023: $306 · 2024: $1,873 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,600 · Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,599.95 |
| Food and Beverage | $1,456.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,615.39 | 2023-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $301.04 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $295.45 | 2022-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $266.91 | 2021-2025 | Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.93 | 2021-2025 | Ofev |
| Inspire Medical Systems, INC. | $136.55 | 2025 | Inspire |
| Pulmonx Corporation | $129.23 | 2019 | |
| Ekos Corporation | $107.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Amgen INC. | $77.41 | 2024-2025 | Tezspire, Uplizna |
| Regeneron Healthcare Solutions, INC. | $52.38 | 2025 | Dupixent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.32 | 2025 | Lifevest |
| Verona Pharma, INC. | $34.88 | 2025 | Ohtuvayre |
| Genzyme Corporation | $31.56 | 2025 | |
| Resmed Corp | $29.16 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $25.16 | 2023 | Tyvaso |
| Abbvie INC. | $25.00 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $24.10 | 2023 | Uptravi, Opsumit |
| Grifols USA, LLC | $22.56 | 2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $20.97 | 2025 | Yupelri |
| Pfizer INC. | $18.95 | 2022 | |
| Mallinckrodt Hospital Products INC. | $17.05 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $16.34 | 2022 | |
| Philips North America LLC | $15.29 | 2022 | |
| La Jolla Pharmaceutical Company | $15.06 | 2025 | Giapreza |
| Veran Medical Technologies, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.